---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-133346"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:13:43.539323+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics reports FY2025 net loss $12.5M; ARDS Phase 2 trial initiation in 1H 2026

## Summary
- Net loss FY2025 $12.5M ($2.93/sh) vs $10.8M ($2.86/sh) in FY2024; cash $13.4M at year end, plus $3.0M raised since.
- Phase 2 trial for agenT-797 in ARDS/hypoxemic pneumonia to initiate 1H 2026; early data by year end.
- GVHD program funded by NIH STTR grant and Mary Gooze award; trial launch May 2026, preliminary data 2H 2026.
- C-Further collaboration provides up to $1.1M non-dilutive funding for PRAME-TCR iNKT in pediatric oncology.
- Appointments: Dr. Terese Hammond as Head of Pulmonary; Melissa Orilall as Principal Financial Officer.

## SEC filing metadata
- accession: 0001193125-26-133346
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/0001193125-26-133346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/inkt-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-133346
- JSON: https://secwatch.observer/filing/0001193125-26-133346.json
- Plain text: https://secwatch.observer/filing/0001193125-26-133346.txt

## Key facts
- Earnings Releases
  MiNK Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Net income: net loss for the quarter ended December 31, 2025, was $2.6 million, or $0.56 per share
  - Result: reported results
  source text: On March 31, 2026, MiNK Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/0001193125-26-133346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.